March 6, 2009 - Takeda Pharmaceutical Company Limited today announced that Takeda Global Research and Development Center, Inc., a wholly owned United States subsidiary, was informed as part of regular discussions about the alogliptin New Drug Application with the USFDA, that although the alogliptin NDA was filed prior to issuance of FDA’s December 2008 guidance on new Type 2 diabetes treatments, the FDA will apply these guidelines when reviewing the alogliptin NDA.
The details can be read here.
No comments:
Post a Comment